Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Acute histologic rejection without biochemical graft dysfunction in liver transplantation

Withholding adjuvant immunosuppression from patients with histologic acute cellular rejection and no biochemical graft dysfunction seems to be safe, find a research team in the latest issue of Liver Transplantation.

News image

fiogf49gjkf04

Protocol biopsy results in the first few weeks after liver transplantation sometimes display histologic features of acute cellular rejection (ACR).

This can occur even in the absence of significant clinical or biochemical dysfunction.

32% of patients with histologic ACR on protocol biopsy had no associated biochemical graft dysfunction.
Liver Transplantation

There is no clear consensus about the need to treat such cases with adjuvant immunosuppression.

In this systematic review, the authors from Auckland, New Zealand, describe the natural history of untreated histologic ACR in the absence of biochemical graft dysfunction.

The team performed an electronic search of the Medline, Embase, and Cochrane Library databases to select studies that reported protocol liver biopsies in the early posttransplant period, between 1983 to 2000.

They selected studies that identified patients with ACR on protocol biopsy, who were not treated with adjuvant immunosuppression, to form the basis of the study group.

Data from individual studies were extracted using standardized pro forma and pooled for descriptive analysis.

The research team identified 3431 studies, of which 516 were cited in full.

Of these, 15 studies met all of the inclusion criteria.

These 15 studies reported on 1566 patients who had protocol biopsies performed in the early posttransplant period, of which 67% had histologic evidence of ACR.

The team found that 32% of patients, with histologic ACR on protocol biopsy, had no associated biochemical graft dysfunction.

Furthermore, without treatment, only 14% of these patients subsequently developed biochemical graft dysfunction requiring adjuvant immunosuppression.

Steroid-resistant rejection and chronic rejection both had a prevalence of 4% in patients with untreated histologic ACR and no biochemical graft dysfunction.

Dr Adam Bartlett's team concluded, "Withholding adjuvant immunosuppression from patients with histologic ACR and no biochemical graft dysfunction seems to be safe, as long as graft function is carefully monitored".

"The rationale for performing protocol biopsies in the absence of biochemical graft dysfunction is questionable".

In a related article in the same publication, Drs George Therapondos and Peter Hayes, from Edinburgh, Scotland, discuss the above article.

They conclude, "Despite…the limitations of this retrospective analysis, we believe that it is safe to abandon routine posttransplant liver biopsies in patients with no evidence of biochemical graft dysfunction".

"The severity of the biochemical abnormality that triggers a biopsy is likely to be dependant on the time since transplantation and further studies to define this more accurately are clearly required".

Liver Transpl 2002; 8: 1147-53
09 December 2002

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us